Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: InvestorLady who wrote (768)	5/7/1998 1:44:00 PM
From: David Israel-Rosen	Read Replies (3) \| Respond to of 1491

Dear Investor lady. Your cup is always half "fool"!!! Tell me what is not clear in the Dow Jones Article ? David Pharmos Head-Trauma, Cancer Drugs In Development Dow Jones Newswires ISELIN, N.J. -- Pharmos Corp.'s (PARS) dexanabinol drug for severe head trauma is in phase II testing and its tamoxifen analog program for cancer treatment is in pre-clinical development. In a press release Thursday, the company said it recently completed enrollment of severe head trauma patients treated with the second dose, 150 milligrams, of dexanabinol in its phase II trial and began enrolling patients to be treated with the third dose, 300 mg. So far, 67 patients have been enrolled with no apparent safety concerns, according to an external safety committee. The mortality rate is about 12%. Pharmos said this rate is low, based on the test population. Pharmos will unblind the first two dosages this summer. The information will help planning of phase III clinical trial in head trauma and Phase II in stroke, as well as in negotiations with partners. The company also continues to develop its tamoxifen analog program. In pre-clinical studies, one analog, tamoxifen methiodide, has shown more tumorcidal activity than tamoxifen. The drug also appeared safer than the base tamoxifen. Pharmos plans to complete pre-clinical development near the end of 1998. Pharmos makes products to treat opthalmic and neurological disorders.